Risk factors for organ/space surgical site infection after hepatectomy for hepatocellular carcinoma in 359 recent cases
Hiroshi Sadamori(Okayama University), Toshiyoshi Fujiwara(Okayama University), Daisuke Satoh(Okayama University), Masashi Utsumi(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Yuzo Umeda(Okayama University), Susumu Shinoura(Okayama University), Kazuhiro Yoshida(Nagasaki University), Takahito Yagi(Okayama University), Ryuichi Yoshida(Okayama University)
Cited by 47
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178